OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
OPKO Health, Inc. announced it will report its second-quarter 2026 operating and financial results on Monday, July 27, 2026. Senior management will host a conference call and webcast at 4:30 p.m. ET to discuss the results, provide a business update, and offer financial guidance. Participants can pre-register for the call or access a webcast through OPKO’s Investor Relations.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health (OPK) is poised for growth due to its BioReference restructuring, 4Kscore sales, digital expansion, and strategic partnerships, including global commercialization of RAYALDEE. While RAYALDEE and a strong pipeline contribute to optimism, the company faces risks from early-stage clinical development, continued operating losses, and overdependence on RAYALDEE sales. Despite these concerns, Zacks maintains a "Hold" rating for OPK.
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
OPKO Health, Inc. will report its second-quarter 2026 financial and operating results on Monday, July 27, 2026. Senior management will host a conference call and webcast at 4:30 p.m. ET to discuss the results, provide a business update, and offer financial guidance. Participants are encouraged to pre-register for the call, and replay options will be available until August 3, 2026.
OPKO Health (OPK) Projected to Announce Earnings on Thursday
OPKO Health (NASDAQ:OPK) is projected to announce its Q2 2026 earnings after market close on Thursday, July 30th. Analysts anticipate an EPS of ($0.08) and revenue of $131.2330 million for the quarter. The company's stock currently has a "Reduce" rating from analysts with an average target price of $1.55, and institutional investors have recently made significant moves in their holdings.
OPKO Health stock steadies as investors weigh recent earnings and pipeline progress
OPKO Health's stock is stabilizing as investors evaluate the company's recent financial performance and the progress of its diagnostic and pharmaceutical pipeline. The company is characterized by modest revenue growth, ongoing R&D investments, and efforts to improve efficiency, reflected in its operating metrics and cash flow. Valuation considers its status as a small- to mid-cap healthcare company still in an investment phase, with future growth tied to pipeline milestones and commercial traction of its diagnostic products.
OPK4048118 Bond Coupon Profile — Rate & Payments
This article provides a coupon profile for the OPK4048118 bond issued by OPKO Health, Inc. with a 3.0% interest rate maturing on February 1, 2033. It details the bond's current coupon rate and announces that the next payment is scheduled for August 3, 2026. The page also offers to unlock more in-depth coupon data and payment schedules for essential bond information.
OPKO Health, Inc. (NASDAQ:OPK) Given Average Recommendation of "Reduce" by Brokerages
Five brokerages have issued an average recommendation of "Reduce" for OPKO Health, Inc. (NASDAQ:OPK), with one analyst assigning a sell rating and four a hold rating. The average one-year target price for the stock is $1.55. Recent analyst adjustments include an upgrade from "sell (e+)" to "sell (d-)" by Weiss Ratings, a move from "sell" to "hold" by Wall Street Zen, and a downgrade from "outperform" to "market perform" by Barrington Research.
OPK4020628 Bond Risk Profile
This article provides a risk profile for the OPK4020628 bond issued by OPKO Health, Inc., which has a 3.0% coupon and matures on February 1, 2033. It focuses on offering key metrics for credit risk assessment, including security level, inflation protection, and issuer ratings, to help investors evaluate the bond's reliability. The page also mentions access to exclusive analyst ratings for bonds to make informed decisions.
OPK4048118 Bond Redemption Profile
This article provides a profile of the OPK4048118 bond issued by OPKO Health, Inc., detailing its redemption overview, type, date, and amount. It also mentions the importance of checking the sinking fund schedule for callable bonds. The content emphasizes accessing key redemption data for current and historical repurchases.
OPK4020628 Bond Profile — Key Metrics
This article provides a detailed profile of the OPKO Health, Inc. 3.0% 01-FEB-2033 bond, identified as OPK4020628. It highlights key financial metrics such as the issue date, maturity date, outstanding amount, and coupon rate. Additionally, it offers a brief company description of OPKO Health, Inc., detailing its biopharmaceutical and diagnostics segments.
OPK5991654 Bond Coupon Profile — Rate & Payments
This article provides a coupon profile for the OPKO Health, Inc. 3.75% 15-JAN-2029 bond, identified as OPK5991654. It details that the current coupon rate is 3.75% and the next interest payment is scheduled for January 15, 2027. The article encourages users to unlock full data for more insights into the bond's payment schedule and rates.
OPK5991654 Bond Profile — Key Metrics
This article provides key metrics for the OPK5991654 bond profile issued by OPKO Health, Inc. The bond has a 3.75% coupon rate and matures on January 15, 2029, with an outstanding amount of $121.38 million. OPKO Health, Inc. is a biopharmaceutical and diagnostics company operating through Diagnostics and Pharmaceuticals segments.
Opko Health(OPK) Stock Options Chain | Quotes & News
The provided content is incomplete and does not allow for a summary of Opko Health's stock options chain, quotes, or news.
OPK5733212 Bond Coupon Profile — Rate & Payments
This article provides a coupon profile for the OPK5733212 bond issued by OPKO Health, Inc. It details the bond's current coupon rate of 3.75% and indicates that the next interest payment is scheduled for July 15, 2026. The page offers an overview of the bond's interest payments and allows users to access more in-depth coupon data and payment schedules.
OPKO Health Inc (OPK) Institutional Confidence
This article analyzes the institutional confidence in OPKO Health Inc (OPK), stating its current institutional shareholding score is 3.00, placing it 55th out of 75 in the Healthcare Providers & Services industry. The institutional shareholding proportion has increased by 22.96% quarter-over-quarter, reaching 31.36%. The largest institutional shareholder is Paul Tudor Jones, holding 214.69K shares, while other significant holders include Frost Gamma Investments Trust and BlackRock Institutional Trust Company, N.A.
OPK5733212 Bond Profile — Key Metrics
This article provides key metrics for the OPK5733212 bond issued by OPKO Health, Inc. The bond has a 3.75% coupon rate, was issued on January 9, 2024, and matures on January 15, 2029, with a face value of $1,000. OPKO Health, Inc. is described as a biopharmaceutical and diagnostics company.
OPK.O - | Stock Price & Latest News
This Reuters page provides real-time financial market data and news related to the stock symbol OPK.O, offering insights for financial market professionals. It includes current stock prices for major indices like SPX, IXIC, and DJI, along with performance data for commodities, currencies, rates, and bonds. The content highlights market trends, showing positive and negative changes across various financial instruments.
Zacks Research Has Weak Estimate for OPKO Health Q2 Earnings
Zacks Research has reduced its Q2 2028 EPS estimate for OPKO Health (NASDAQ:OPK) to -$0.05 from -$0.04, reflecting a weaker outlook, though the full-year estimate remains at -$0.29 per share. This follows the company's recent quarterly results where EPS matched expectations at -$0.07, but revenue of $124.2 million fell below forecasts and declined 17.1% year-over-year. Wall Street analysts currently hold a "Reduce" rating for OPKO Health with a consensus target price of $1.55.
ETFs Investing in OPKO Health, Inc. Stocks
This article lists various ETFs that invest in OPKO Health, Inc. stocks. It provides a detailed table including each ETF's market value, weight of OPKO in its holdings, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different investment focuses such as small-cap, health care, and total market, offering diverse opportunities for investors interested in OPKO Health.
OPKO Health (OPK) Piper Sandler 36th Annual Healthcare Conference Summary
OPKO Health presented at the Piper Sandler 36th Annual Healthcare Conference, highlighting the growth of its Ngenla human growth hormone, with Pfizer projecting $500 million to $1 billion in near-term sales. The company also discussed its ModeX platform for multispecific antibodies, partnerships with BARDA and Merck, and a strong financial position with over $400 million in cash. OPKO Health is pursuing strategic partnerships and non-dilutive funding to advance its diverse R&D pipeline.
OPK - Opko Health Inc Options
This article provides a comprehensive overview of Opko Health Inc. (OPK) stock, including its latest closing price, key financial metrics, performance indicators, and ownership details. It details statistics such as market capitalization, income, sales, P/E ratio, EPS, insider and institutional ownership, and various performance percentages over different periods.
OPKO Health Inc focuses on diagnostics and pharmaceuticals as investors weigh long-term prospects
OPKO Health Inc is building its business around both diagnostic services and specialty pharmaceutical products. The company aims to diversify its revenue streams and capitalize on growth opportunities in the healthcare sector. Investors are closely monitoring OPKO's strategy for balancing investments, fostering innovation, and achieving profitability in the long run.
Form 13D/A OPKO HEALTH For: 1 July By Investing.com
This article announces that OPKO Health has filed a Form 13D/A for July 1st. It also includes general market data, popular news, and various financial statistics. The content itself provides no further details beyond the filing announcement.
Form 13D/A OPKO HEALTH For: 1 July By Investing.com
This article announces the filing of a Form 13D/A for OPKO Health on July 1st. It also includes various market data, such as indices, commodities, and stock performances, alongside popular news headlines.
Phillip Frost (NASDAQ: OPK) reports 34.1% beneficial stake in OPKO
Phillip Frost has reported a significant 34.1% beneficial stake in OPKO Health (NASDAQ: OPK), totaling 255,429,406 shares. This ownership includes holdings through Gamma Trust, Frost Nevada Investments Trust, a philanthropic foundation, stock options, and restricted stock units. The amendment to the SEC filing (SCHEDULE 13D/A) was filed due to a change in OPKO's outstanding share count, which is now 746,328,225 shares as of June 29, 2026, rather than any recent transactions by Frost or his affiliated trusts.
ETFs Investing in OPKO Health, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of OPKO Health, Inc. (OPK), primarily traded on the Mexican Stock Exchange. The ETFs are presented with detailed financial metrics including market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The information aims to assist investors by providing a consolidated view of funds that offer exposure to OPKO Health, Inc.
Enterprise value to EBITDA forward of Opko Health, Inc. – NASDAQ:OPK
This article presents financial data for Opko Health, Inc. (NASDAQ: OPK), specifically focusing on its enterprise value to EBITDA forward metric. The content was sourced from TradingView and includes general company and market information, but the specific financial value for the metric is not provided in the snippet.
OPKO Health, Inc. Actuals & Estimates (BMV:OPK)
This article provides an overview of OPKO Health, Inc. (BMV:OPK) stock, including current price, analyst forecasts, historical highs and lows, volatility, market capitalization, and financial reports. It also details recent earnings, revenue, net income, and confirms that the company does not pay dividends.
Price to earnings forward of OPKO Health, Inc. – FWB:XCY
This article provides a financial metric, the "Price to earnings forward," for OPKO Health, Inc. (FWB:XCY) on the TradingView platform. It indicates that the company's financial data is available for review, though no specific values are presented in this snippet. The content primarily acts as a placeholder or a link to more detailed financial information.
Price to sales forward of Opko Health, Inc. – NASDAQ:OPK
This page from TradingView displays information related to the forward price-to-sales ratio for Opko Health, Inc. (NASDAQ: OPK). It indicates that the content is a financial data point for the company, accessible through the platform's market data and financial tools. The page itself does not present specific numerical data but rather serves as a label or heading within the TradingView interface.
Price to book forward of OPKO Health, Inc. – FWB:XCY
The article focuses on the "Price to book forward" metric for OPKO Health, Inc. (FWB:XCY) listed on the Frankfurt Stock Exchange. It provides financial data context without presenting specific values in the clean content. The page also outlines various features and services offered by TradingView.
OPKO Health, Inc. Actuals & Estimates (NASDAQ:OPK)
This article provides an overview of OPKO Health, Inc. (NASDAQ: OPK) stock, including its current price, market capitalization, historical highs and lows, and analyst forecasts. It also details the company's financial actuals and estimates for earnings and revenue, noting that OPK does not pay dividends.
XCY Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for OPKO Health, Inc. (XCY) stock based on analyst opinions. It includes details on the company's past performance, earnings, revenue, and other financial metrics. The article also addresses frequently asked questions about XCY, such as its all-time high and low prices and upcoming earnings reports.
OPKO Health, Inc. Actuals & Estimates (TASE:OPK)
This article provides an overview of OPKO Health, Inc. (TASE:OPK) stock, including its current price, performance, analyst forecasts, and financial data. It covers historical price movements, market capitalization, earnings reports, revenue, EBITDA, and employee count, alongside guidance on how to buy the stock and its technical analysis ratings.
OPK Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and price target for Opko Health, Inc. (OPK) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical highs and lows, financial data like earnings and revenue forecasts, and other relevant company information such as market capitalization and employee count. The article also addresses frequently asked questions about investing in OPK.
OPK Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and financial overview for OPKO Health, Inc. (OPK), including analyst price targets, historical stock performance, and future earnings estimates. It covers various metrics like stock volatility, market capitalization, revenue, net income, and upcoming earnings dates. The piece also includes a disclaimer that the information is not investment advice.
OPKO Health (OPK) Stock Could Be 57% Undervalued As Margin Recovery Comes Into Focus
OPKO Health (OPK) is currently trading at $1.46, with analysts suggesting it could be 57% undervalued, pointing to a fair value of $3.40. This valuation is based on expected margin recovery after the sale of BioReference's oncology assets, aiming for profitability in its Diagnostics segment by 2025. Despite recent share price momentum, the company faces ongoing net losses and high R&D spending, and its current P/S ratio of 1.9x is higher than the industry average, raising valuation risk.
OPKO HEALTH (OPK) director receives 80,000-share stock option grant
OPKO Health director Uppaluri Subbarao V received a grant of stock options for 80,000 shares as part of standard director compensation. These options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. The grant involved canceling a prior 50,000-option grant, issuing 30,000 new options, and reissuing 50,000 options.
Director at OPKO (NASDAQ: OPK) receives grant of 60,000 stock options
OPKO Health, Inc. director Richard C. Pfenniger Jr. was granted 60,000 stock options with an exercise price of $1.42 per share. These options become exercisable on June 18, 2027, and expire on June 17, 2036. This transaction was reported via an SEC Form 4 filing, indicating an award of derivative securities, not a market purchase or sale.
Form 4 Opko Health For: 22 June By Investing.com
The article "Form 4 Opko Health For: 22 June" by Investing.com reports on a Form 4 filing for Opko Health (OPK) dated June 22, 2026. This brief piece, which appears to be a standard financial markets update, mentions the company's stock performance (+2.74%) and reiterates the Form 4 filing information without further details on its content. The remainder of the provided text consists of extensive navigation elements, market data tables, and promotional content rather than specific article details.
Opko Health (OPK) director Roger Medel receives 30,000 stock options grant
Opko Health (OPK) director Roger Medel has been granted 30,000 stock options, with an exercise price of $1.42 per share. These options will become exercisable on June 18, 2027, and have an expiration date of June 17, 2036. This transaction is considered a grant or award of derivative securities, not an open-market purchase or sale.
Opko Health (OPK) director awarded 30,000 stock options at $1.42 strike
OPKO Health director John A. Paganelli was granted 30,000 stock options at an exercise price of $1.42 per share as compensation. These options become exercisable on June 18, 2027, and will expire on June 17, 2036. Following this grant, Paganelli directly holds 30,000 options.
Form 4 Opko Health For: 22 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Opko Health (OPK) dated June 22. It provides no further details on the filing but lists common financial market data, including indices, commodities, and stock prices. The piece appears to be a placeholder or automated post for regulatory filings.
OPKO Health (OPK) director receives 30,000-share stock option award at $1.42
OPKO Health director Prem A. Lachman was granted options for 30,000 shares of common stock at an exercise price of $1.42 per share on June 18, 2026. This award is compensation-related, not an open-market transaction, and brings his directly held option position to 30,000 shares which expire on June 17, 2036. The transaction is coded as an 'A' transaction, signifying a routine grant or award, and is considered neutral in terms of market impact.
Opko Health Shareholders Back Board, Equity and Auditors
Opko Health shareholders re-elected all eleven nominees to the Board of Directors, approved the 2026 Equity Incentive Plan, and endorsed executive compensation at their Annual Meeting. They also ratified Ernst & Young LLP as the independent auditor. Despite weak financial performance noted by TipRanks' AI Analyst, the company maintains a "Buy" rating from analysts with a $3.00 price target.
OPKO Health Inc (OPK) Financial Health: Profitability & Balance Sheet Analysis
OPKO Health Inc (OPK) currently holds a financial score of 7.66, ranking 38 out of 76 in the Healthcare Providers & Services industry, indicating a robust financial status and high operating efficiency. Despite this, its latest quarterly revenue saw a 17.18% year-over-year decrease to $124.20 million, and net profit declined by 18.88% year-over-year. The report highlights specific financial dimensions like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, noting that detailed relevant data has not yet been disclosed by the company for several categories.
OPKO Health (OPK) AGM 2026 Summary
This article summarizes OPKO Health's (OPK) 2026 Annual General Meeting. Key outcomes included the approval of all four shareholder proposals, such as the election of directors and the 2026 equity incentive plan. The summary also highlights recent company events, including clinical milestones, proxy filings, and quarterly results.
OPKO Health Inc (OPK) Valuation: PE, PB & Fair Value Analysis
OPKO Health Inc (OPK) has a current valuation score of 7.86, placing it 57th out of 76 in the Healthcare Providers & Services industry. The company's P/E ratio stands at -5.18, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
OPKO Health Inc (OPK) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of OPKO Health Inc (OPK), detailing its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests that the stock is currently suitable for range-bound swing trading, with indicators providing a mixed signal지만 leaning towards a "Buy" based on moving averages.
OPKO Health Inc (OPK) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for OPKO Health Inc (OPK), stating its current risk score is 6.17, ranking 31 out of 76 in the Healthcare Providers & Services industry. It highlights the company's beta of 1.47, indicating higher volatility compared to the S&P 500. Various metrics like VaR, maximum drawdown, volatility, and Sharpe Ratio are detailed, along with liquidity metrics, to offer a comprehensive overview of OPK's risk profile.
